Anika Therapeutics Jumps 20% on FDA Letter

From BioHealth Investor

Shares of Anika Therapeutics (ANIK) jumped more than 20% on Tuesday after the company announced it had received an approvable letter from the FDA regarding its Cosmetic Tissue Augmentation (CTA) product.

CTA is an injectable filler used for facial wrinkles and other cosmetic procedures. It is based on Anika’s proprietary modified hyaluronic acid, and includes the common anesthetic Lidocaine.

The company expects final approval by end of 2006 and commercialization by mid-2007. The company intends on refiling with the FDA and European Union to enhance product features before commercial launch.

The company’s financials have been looking great as both revenues and net earning have been increasing over the last few years.

The company holds almost $50 million in cash and no debt, and is currently worth less than $150 million on the market.

Shares of Anika closed at $13.90 a share, near its 52-week high of $15.37

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.